Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19295254 | FORMULATIONS OF VIMSELTINIB | August 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19286812 | Biphenyl and Phenylpyridine Compounds | July 2025 | December 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 19079070 | FORMULATIONS OF VIMSELTINIB | March 2025 | May 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19018702 | ILOPROST COMPOSITIONS AND FORMULATIONS THEREOF | January 2025 | July 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18980262 | TREATMENT OF ADENOVIRUS INFECTION OR DISEASE ASSOCIATED WITH ADENOVIRUS INFECTION | December 2024 | December 2025 | Allow | 12 | 2 | 0 | No | No |
| 18965591 | METHOD OF TREATMENT WITH MILSAPERIDONE | December 2024 | September 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18952791 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | November 2024 | November 2025 | Abandon | 12 | 2 | 0 | No | No |
| 18832248 | GINGERENONE A PRODRUGS AS SENSOTHERAPEUTICS AND METHODS OF USE | July 2024 | April 2025 | Allow | 8 | 0 | 1 | Yes | No |
| 18656519 | TREATMENT OF ADENOVIRUS INFECTION OR DISEASE ASSOCIATED WITH ADENOVIRUS INFECTION | May 2024 | March 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18616046 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | March 2024 | November 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18431805 | METHOD OF TREATING CANCER WITH COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS (HDACI) SUBSTANCES | February 2024 | September 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18409952 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONS | January 2024 | February 2025 | Allow | 14 | 0 | 0 | Yes | No |
| 18529946 | Treatment of Multiple Sclerosis Comprising DHODH Inhibitors | December 2023 | August 2025 | Allow | 21 | 1 | 0 | No | No |
| 18565762 | COMPOSITIONS CONTAINING AND THERAPIES USING BEMPEDOIC ACID AND TOLVAPTAN | November 2023 | March 2026 | Allow | 27 | 0 | 0 | No | No |
| 18503992 | LIQUID FORMULATIONS OF INDACATEROL | November 2023 | August 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18502240 | TREATING IRON DEFICIENCY WITH FERRIC CARBOXYMALTOSE | November 2023 | September 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18502589 | COMPOSITIONS AND USES THEREOF FOR TREATMENT OF IDIOPATHIC PRETERM BIRTH | November 2023 | June 2025 | Allow | 20 | 0 | 0 | No | No |
| 18500199 | APPARATUS AND METHOD FOR CRYOGRANULATING A PHARMACEUTICAL COMPOSITION | November 2023 | August 2025 | Allow | 21 | 0 | 0 | Yes | No |
| 18494950 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS | October 2023 | July 2025 | Allow | 21 | 1 | 0 | No | No |
| 18486795 | HEMOSTATIC DEVICES | October 2023 | March 2026 | Allow | 29 | 2 | 0 | No | No |
| 18484252 | METHOD FOR AMELIORATING PROGRESSION OF RENAL FIBROSIS AND TREATING RENAL FIBROSIS BY 5-(2',4'-DIFLUOROPHENYL)-SALICYLANILIDE DERIVATIVES | October 2023 | July 2025 | Allow | 21 | 1 | 0 | No | No |
| 18474535 | STABLE ORAL SUSPENSIONS OF BACLOFEN | September 2023 | March 2025 | Allow | 17 | 0 | 0 | Yes | No |
| 18371229 | METHODS OF TREATING LIVER DISORDERS OR LIPID DISORDERS WITH A THR-BETA AGONIST | September 2023 | September 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18471849 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | September 2023 | September 2025 | Allow | 24 | 3 | 1 | Yes | Yes |
| 18370633 | METHODS OF CONTROLLING MYOCARDIAL BLOOD FLOW | September 2023 | September 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18282365 | ROLLED ORAL THIN FILMS HAVING A HIGH LEVEL OF ACTIVE-INGREDIENT LOADING | September 2023 | February 2026 | Allow | 29 | 0 | 0 | No | No |
| 18463000 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | September 2023 | September 2025 | Allow | 24 | 1 | 0 | No | No |
| 18238961 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER | August 2023 | December 2025 | Allow | 27 | 0 | 0 | No | No |
| 18231035 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING CALCIPHYLAXIS | August 2023 | June 2025 | Allow | 22 | 1 | 0 | No | No |
| 18226711 | Threonate Compounds and Methods of Use Thereof | July 2023 | August 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18346721 | COMPOSITIONS AND METHODS OF USING PROPYLENE SULFIDE-BASED POLYMERS FOR TREATMENT OF CHAGAS DISEASE | July 2023 | January 2025 | Allow | 19 | 0 | 0 | Yes | No |
| 18215989 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING TISSUE CALCIFICATION | June 2023 | March 2025 | Allow | 20 | 0 | 0 | Yes | No |
| 18216405 | METHODS FOR TREATING MULTIPLE MYELOMA AND THE USE OF COMPANION BIOMARKERS FOR 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE | June 2023 | August 2025 | Allow | 26 | 1 | 0 | Yes | No |
| 18255229 | FIXED COMBINATION MEDICINE FOR THE CONTROL AND MANAGEMENT OF NEUROPATHIC PAIN | May 2023 | March 2026 | Allow | 33 | 1 | 0 | No | No |
| 18254753 | PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP | May 2023 | February 2026 | Allow | 33 | 0 | 1 | Yes | No |
| 18201079 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | May 2023 | August 2025 | Allow | 27 | 1 | 0 | Yes | No |
| 18321968 | COMPOSITIONS AND METHODS FOR REDUCING LAMINITIS OF AN ANIMAL HOOF | May 2023 | April 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18311846 | PHARMACEUTICAL COMBINATION, COMPOSITION AND COMPOUND PREPARATION CONTAINING GLUCOKINASE ACTIVATOR AND K-ATP CHANNEL BLOCKER, PREPARATION METHOD THEREFOR AND USE THEREOF | May 2023 | April 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18142308 | METHODS AND COMPOSITIONS TO TREAT CANCER | May 2023 | January 2025 | Allow | 21 | 1 | 0 | No | No |
| 18141666 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | May 2023 | September 2025 | Allow | 29 | 1 | 0 | Yes | No |
| 18140128 | DEUTERATED RUC-4 | April 2023 | August 2025 | Abandon | 27 | 1 | 0 | Yes | No |
| 18138306 | MODULATORS OF GTPASES AND THEIR USE | April 2023 | March 2025 | Allow | 23 | 1 | 0 | No | No |
| 18133323 | METHODS AND COMPOSITIONS FOR TREATING ECTOPARASITE INFESTATIONS | April 2023 | September 2025 | Abandon | 30 | 1 | 1 | No | No |
| 18123702 | METHOD FOR THERAPEUTIC TREATMENT OF ROSACEA | March 2023 | January 2025 | Allow | 22 | 0 | 0 | Yes | No |
| 18173865 | Patentiflorin A Analogs as Antiviral Agents | February 2023 | February 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18019486 | THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS | February 2023 | January 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18078628 | COMPOSITIONS AND METHODS FOR THE TOPICAL ADMINISTRATION OF SPIRONOLACTONE FOR THE TREATMENT OF CUTANEOUS SIGNS OF EXCESS ANDROGEN AND CHRONIC STRESS RESPONSE | December 2022 | July 2025 | Allow | 32 | 2 | 0 | No | No |
| 18077931 | Threonate Compounds and Methods of Use Thereof | December 2022 | May 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18056804 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | November 2022 | June 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17999145 | METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME WITH ACTIVATORS OF TIE-2 | November 2022 | October 2025 | Allow | 35 | 1 | 0 | No | No |
| 17925075 | COMBINATION COMPRISING TRICYCLE COMPOUND AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING HBV | November 2022 | January 2026 | Allow | 38 | 1 | 1 | No | No |
| 17924802 | COMPOUND FOR TREATING AND/OR PREVENTING DISEASES CAUSED BY CORONAVIRUS AND USE THEREOF | November 2022 | December 2025 | Allow | 37 | 0 | 1 | Yes | No |
| 17998195 | THERAPEUTIC AGENT FOR VASCULAR DISORDER | November 2022 | January 2026 | Allow | 38 | 1 | 0 | No | No |
| 18046916 | COMPOSITIONS AND METHODS FOR REDUCING SKIN FAT | October 2022 | December 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 18046917 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | October 2022 | December 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17907681 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTION-INDUCED CARDIOMYOPATHY | September 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17907451 | COMPOSITIONS CONTAINING AMINO ACIDS AND METHODS OF USING SUCH COMPOSITIONS FOR TREATING SARCOPENIA | September 2022 | November 2025 | Allow | 38 | 1 | 0 | No | No |
| 17914529 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF COVID-19 | September 2022 | January 2026 | Allow | 40 | 1 | 1 | Yes | No |
| 17912711 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF THREATENED RESPIRATORY FAILURE CAUSED BY CORONAVIRUS INFECTION AND DISEASE | September 2022 | March 2026 | Allow | 42 | 1 | 0 | Yes | No |
| 17909513 | TREATMENT OF PAIN BY TARGETING NR4A1 | September 2022 | January 2026 | Allow | 41 | 1 | 0 | Yes | No |
| 17905686 | Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019 | September 2022 | October 2025 | Allow | 38 | 1 | 0 | No | No |
| 17909302 | IBOGAINE ANALOGS AS THERAPEUTICS FOR NEUROLOGICAL AND PSYCHIATRIC DISORDERS | September 2022 | October 2025 | Allow | 38 | 1 | 0 | No | No |
| 17901356 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF ITCH | September 2022 | May 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 17892585 | COMPOSITIONS AND METHODS FOR TREATING RENAL INJURY | August 2022 | December 2025 | Allow | 40 | 1 | 0 | No | No |
| 17801199 | STARCH PROPIONATE USED AS A FOOD ADDITIVE AND/OR DIETARY SUPPLEMENT FOR PREVENTION OF OVERWEIGHT AND OBESITY | August 2022 | March 2026 | Abandon | 43 | 2 | 0 | No | No |
| 17820387 | COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS | August 2022 | September 2025 | Allow | 37 | 1 | 0 | No | No |
| 17798502 | TREATMENT AND PREVENTION OF CAPILLARY MALFORMATION-ARTERIOVENOUS MALFORMATION | August 2022 | June 2025 | Allow | 34 | 1 | 0 | No | No |
| 17760239 | IMPROVED TREATMENT OF ATOPIC DERMATITIS WITH TRADIPITANT | August 2022 | March 2026 | Allow | 43 | 3 | 0 | No | No |
| 17796076 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | August 2022 | January 2026 | Allow | 42 | 2 | 1 | Yes | No |
| 17759488 | TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS FOR TREATMENT OF RENAL DISEASE | July 2022 | January 2026 | Abandon | 41 | 1 | 1 | No | No |
| 17794820 | Compositions for Inhibition of Herpesviruses | July 2022 | March 2026 | Allow | 43 | 1 | 1 | No | No |
| 17792380 | COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE PREVENTION AND TREATMENT OF CHEMOTHERAPY SIDE EFFECTS | July 2022 | July 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17788146 | MANAGING MICROBIAL DYSBIOSIS WITH TEMOCILLIN | June 2022 | April 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17788210 | Composition and methods for treating pathogenic infections on wounds | June 2022 | September 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17785394 | ANTIVIRAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | June 2022 | January 2026 | Allow | 43 | 1 | 1 | No | No |
| 17784587 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | June 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17834380 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | June 2022 | November 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17756800 | PHARMACEUTICAL COMPOSITION COMPRISING STEROID COMPOUND AND OLOPATADINE | June 2022 | October 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17779763 | PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES CHARACTERIZED BY COMPRISING COMBINATION OF INTEGRASE INHIBITOR AND ANTI-HIV AGENT | May 2022 | October 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17743388 | METHOD OF PREPARING NANOPARTICLES COMPRISING POORLY WATER SOLUBLE DRUGS FOR TREATING HEPATITIS | May 2022 | April 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17740970 | COMPOSITIONS, METHODS AND KITS FOR ALTERING ADIPOCYTES | May 2022 | October 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17713746 | PHARMACEUTICAL COMPOSITION FOR TOPICAL WOUND TREATMENT | April 2022 | December 2024 | Allow | 32 | 0 | 1 | Yes | No |
| 17642287 | AGENT FOR PROTECTION OF BLOOD BRAIN SPINAL CORD BARRIER | March 2022 | February 2025 | Allow | 35 | 1 | 1 | Yes | No |
| 17632543 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF THEIR USE IN REVERSING CANCER CHEMORESISTANCE | February 2022 | February 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17578780 | Methods for Treating Ascites | January 2022 | February 2024 | Abandon | 25 | 2 | 0 | Yes | No |
| 17576623 | Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress | January 2022 | June 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17558169 | THERAPY AND PREVENTION OF PRION PROTEIN COMPLEX INFECTIONS IN NON-HUMAN ANIMALS | December 2021 | March 2025 | Allow | 39 | 0 | 0 | Yes | No |
| 17618066 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | December 2021 | September 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17528017 | Methods of Treating Prostate Cancer | November 2021 | March 2025 | Allow | 40 | 1 | 0 | No | No |
| 17524304 | METHODS OF REGULATING OXIDOREDUCTASE ACTIVITY FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). | November 2021 | March 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17516449 | METHODS OF TREATMENT FOR DISEASE FROM CORONAVIRUS EXPOSURE | November 2021 | October 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17489349 | COMPOSITIONS AND METHODS FOR PAIN RELIEF AND NUMBING | September 2021 | October 2024 | Abandon | 37 | 3 | 1 | Yes | No |
| 17255414 | METHODS AND USES OF COLCHICINE DERIVATIVES | December 2020 | February 2025 | Allow | 50 | 3 | 1 | Yes | No |
| 17074547 | IMMUNOTHERAPY FOR PREVENTION AND EARLY TREATMENTS FOR COVID-19 INFECTION | October 2020 | October 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16462317 | PYRIDONE DERIVATIVE PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF | May 2019 | March 2020 | Allow | 10 | 1 | 0 | No | No |
| 16341523 | Prevention and treatment of human metabolic syndrome including type 2 diabetes, steatohepititis and related conditions using non-absorbable, orally administered compounds | April 2019 | September 2020 | Allow | 17 | 0 | 1 | Yes | No |
| 16370677 | CROMOLYN COMPOSITIONS FOR TREATMENT OF PULMONARY FIBROSIS | March 2019 | October 2019 | Allow | 7 | 1 | 1 | No | No |
| 16370681 | CROMOLYN COMPOSITIONS FOR TREATMENT OF PULMONARY FIBROSIS | March 2019 | October 2019 | Allow | 6 | 1 | 0 | No | No |
| 16360139 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS IN THE TREATMENT OF NEOPLASMS | March 2019 | June 2020 | Allow | 15 | 1 | 0 | Yes | No |
| 16284461 | COMPOSITIONS AND METHODS OF USE OF PHORBOLESTERS | February 2019 | May 2020 | Allow | 14 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAO, SAVITHA M.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 46.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner RAO, SAVITHA M works in Art Unit 1691 and has examined 92 patent applications in our dataset. With an allowance rate of 95.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner RAO, SAVITHA M's allowance rate of 95.7% places them in the 85% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by RAO, SAVITHA M receive 1.98 office actions before reaching final disposition. This places the examiner in the 49% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by RAO, SAVITHA M is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +1.2% benefit to allowance rate for applications examined by RAO, SAVITHA M. This interview benefit is in the 19% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 32.9% of applications are subsequently allowed. This success rate is in the 70% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 55.2% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 92.9% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 76.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 34.8% are granted (fully or in part). This grant rate is in the 22% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 1.1% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.3% of allowed cases (in the 70% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.